Loading clinical trials...
Loading clinical trials...
Hepatobilliary manifestations as extraintestinal manifestations of IBD are sometimes underdiagnosed which can impair patient prognosis
Non alcoholic fatty liver is aliver disease most commonly found in patient with IBD most commonly without intestinal activity. On the other hand primary according cholangitis is the most common specific with IBD commonly with ulcerative colitis. and is commonly overlap with autoimmune hepatitis IBD therapy can also be a cause it can lead to hepatic toxicity and some drugs like ant TNF can cause hepatitis b virus activation.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Start Date
December 1, 2020
Primary Completion Date
December 1, 2021
Completion Date
June 1, 2022
Last Updated
November 13, 2020
60
ESTIMATED participants
Lead Sponsor
Assiut University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions